Literature DB >> 1500019

A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage Ib-IIa cervical cancer patients with pelvic lymph node metastases.

M H Tattersall1, C Ramirez, M Coppleson.   

Abstract

Seventy-one patients with Stage Ib-IIa cervical cancer treated by radical hysterectomy and found to have pelvic lymph node metastases were entered on a randomized trial comparing standard pelvic radiotherapy versus three cycles of combination chemotherapy with cisplatin, vinblastine, and bleomycin followed by pelvic radiotherapy. After a median follow-up of 2.5 years, 24 patients have relapsed. In 12 patients, the first evidence of relapse was in the pelvis, in 11 patients the first relapse was evident at a distant site, and in 1 patient the local recurrence and distant metastases were documented simultaneously. No difference in disease-free or overall survival has emerged between the two treatment groups. Relapse was more common in patients with non-squamous tumors (44%) and in those with metastases in several pelvic lymph nodes. We conclude that patients with pelvic lymph node metastases have a rather poor prognosis, but it remains to be determined how they should best be treated after radical surgery.

Entities:  

Mesh:

Year:  1992        PMID: 1500019     DOI: 10.1016/0090-8258(92)90251-d

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  11 in total

1.  Factors affecting platinum sensitivity in cervical cancer.

Authors:  Rina Kato; Kiyoshi Hasegawa; Yutaka Torii; Yasuhiro Udagawa; Ichio Fukasawa
Journal:  Oncol Lett       Date:  2015-09-25       Impact factor: 2.967

Review 2.  Adjuvant platinum-based chemotherapy for early stage cervical cancer.

Authors:  Daniela D Rosa; Lídia R F Medeiros; Maria I Edelweiss; Paula R Pohlmann; Airton T Stein
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

3.  Patients treated with neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-year follow-up.

Authors:  Daniela Luvero; Francesco Plotti; Alessia Aloisi; Stella Capriglione; Roberto Ricciardi; Andrea Miranda; Salvatore Lopez; Giuseppe Scaletta; Giovanna De Luca; Pierluigi Benedetti-Panici; Roberto Angioli
Journal:  Med Oncol       Date:  2016-08-30       Impact factor: 3.064

Review 4.  Comparative Study of Neoadjuvant Chemotherapy Followed by Definitive Chemoradiotherapy Versus Definitive Chemoradiotherapy Alone in Locally Advanced Carcinoma of Cervix.

Authors:  Aradhna Tripathi; Shyamji Rawat
Journal:  J Obstet Gynaecol India       Date:  2019-07-13

Review 5.  Adjuvant platinum-based chemotherapy for early stage cervical cancer.

Authors:  Frederico S Falcetta; Lídia Rf Medeiros; Maria I Edelweiss; Paula R Pohlmann; Airton T Stein; Daniela D Rosa
Journal:  Cochrane Database Syst Rev       Date:  2016-11-22

6.  The prognosis of women with stage IB1-IIB node-positive cervical carcinoma after radical surgery.

Authors:  Xi Cheng; Shumo Cai; Ziting Li; Meiqin Tang; Muquan Xue; Rongyu Zang
Journal:  World J Surg Oncol       Date:  2004-12-18       Impact factor: 2.754

7.  Comparison of the efficacy among multiple chemotherapeutic interventions combined with radiation therapy for patients with cervix cancer after surgery: A network meta-analysis.

Authors:  Lei Chang; Ruixia Guo
Journal:  Oncotarget       Date:  2017-07-25

8.  Promising treatment results of adjuvant chemotherapy following radical hysterectomy for intermediate risk stage 1B cervical cancer.

Authors:  Tae Yeon Lee; Yi Jo Jeung; Chun Jun Lee; Heung Yeol Kim; Sung Han Kim; Won Gyu Kim
Journal:  Obstet Gynecol Sci       Date:  2013-01-09

9.  The influence of number of high risk factors on clinical outcomes in patients with early-stage cervical cancer after radical hysterectomy and adjuvant chemoradiation.

Authors:  Soyi Lim; Seok-Ho Lee; Kwang Beom Lee; Chan-Yong Park
Journal:  Obstet Gynecol Sci       Date:  2016-05-13

10.  Moving beyond the Cox proportional hazards model in survival data analysis: a cervical cancer study.

Authors:  Lixian Li; Zijing Yang; Yawen Hou; Zheng Chen
Journal:  BMJ Open       Date:  2020-07-19       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.